# Bennu Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bennu-biotherapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $15M
- Latest round: Angel (Aug 15, 2022)
- Investors on record: 6

## About

Founded in 2021 and based in Shanghai, China, Bennu Biotherapeutics is a biotech company that focuses on research and development of cell therapy technology. The company was co-founded by Chen Dong, GL Ventures, Chende Capital, and other institutions. Ping Zhao is the co-founder and CEO of the company.

The company's main products are T cell fate regulation target development platform and T cell engineering transformation platform. As of 2022, the company is carrying out the production process development and pharmacological and toxicological experiments of the product BEN101. The company's products are used in the fields of oncology and autoimmune diseases.

## Funding rounds

- Angel, Aug 15, 2022, $15M — Witruth Capital, INCE Capital, Beijing Life Science Park Innovation Investment Fund
- Angel, Feb 9, 2022 — CD Capital, Shanghai AppTec, GL Ventures

## Investors

- CD Capital — Angel
- Shanghai AppTec — Angel
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel
- Witruth Capital — Angel
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Angel
- Beijing Life Science Park Innovation Investment Fund — Angel